Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
68.29
-0.21 (-0.31%)
At close: Nov 18, 2026, 4:00 PM EST
68.20
-0.09 (-0.13%)
Pre-market: Nov 19, 2026, 9:07 AM EST
Exelixis Employees
Exelixis had 1,077 employees as of December 31, 2025. The number of employees decreased by 70 or 6.10% compared to the previous year. That makes Exelixis the 14,356th largest employer in the world and 2,125th in the United States.
Employees
1,077
Change (1Y)
-70
Growth (1Y)
-6.10%
Revenue / Employee
$2,318,348
Profits / Employee
$821,857
Market Cap
16.66B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,077 | -70 | -6.10% |
| Dec 31, 2024 | 1,147 | -163 | -12.44% |
| Dec 31, 2023 | 1,310 | 87 | 7.11% |
| Dec 31, 2022 | 1,223 | 269 | 28.20% |
| Dec 31, 2021 | 954 | 181 | 23.42% |
| Dec 31, 2020 | 773 | 156 | 25.28% |
| Dec 31, 2019 | 617 | 133 | 27.48% |
| Dec 31, 2018 | 484 | 112 | 30.11% |
| Dec 31, 2017 | 372 | 85 | 29.62% |
| Dec 31, 2016 | 287 | 172 | 149.57% |
| Dec 31, 2015 | 115 | 17 | 17.35% |
| Dec 31, 2014 | 98 | -129 | -56.83% |
| Dec 31, 2013 | 227 | 53 | 30.46% |
| Dec 31, 2012 | 174 | -26 | -13.00% |
| Dec 31, 2011 | 200 | -183 | -47.78% |
| Dec 31, 2010 | 383 | -293 | -43.34% |
| Dec 31, 2009 | 676 | 0 | - |
| Dec 31, 2008 | 676 | -59 | -8.03% |
| Dec 31, 2007 | 735 | 84 | 12.90% |
| Dec 31, 2006 | 651 | 101 | 18.36% |
| Dec 31, 2005 | 550 | 33 | 6.38% |
| Dec 31, 2004 | 517 | -56 | -9.77% |
| Dec 31, 2003 | 573 | 23 | 4.18% |
| Dec 31, 2002 | 550 | -21 | -3.68% |
| Dec 31, 2001 | 571 | 214 | 59.94% |
| Dec 31, 2000 | 357 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,000 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
| Ascendis Pharma | 1,189 |
EXEL News
- 1 day ago - Exelixis Transcript: Jefferies Global Healthcare Conference - Transcripts
- 2 days ago - Exelixis Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 6 days ago - Exelixis price target lowered to $57 from $60 at Morgan Stanley - TheFly
- 7 days ago - Exelixis Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 8 days ago - Exelixis Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 15 days ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November - Business Wire
- 17 days ago - Exelixis price target raised to $78 from $56 at H.C. Wainwright - TheFly
- 19 days ago - Exelixis price target raised to $60 from $53 at Morgan Stanley - TheFly